Inovio electroporation. May 27, 2022 · INOVIO's DNA medicines immunotherapy in combination with Libtayo® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients INO-5401 + INO-9012 + Libtayo ® elicits cancer antigen-specific T cells 55% of MGMT methylated subjects remain alive at a median of 32. If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. D. Mathiesen was BLUE BELL, Pa. Inovio s electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. INO-4800 is in preclinical studies and is planned to advance into Phase 1 clinical trials in the U Nov 14, 2006 · Inovio Biomedical Corp. , Feb. Jun 1, 2009 · Inovio’s strategic intellectual property platform consists of an advanced DNA vaccine design technology; a multi-candidate preclinical and clinical DNA vaccine pipeline, with much of the development work funded by partners and collaborators; a compelling DNA delivery technology based on electroporation; and a significant patent estate. Simply select your manager software from the list below and click Download. Jun 1, 2022 · Intradermal injection of INO-4800 followed by electroporation at 0 and 4 weeks preceded an optional booster 6-10. 7, 2011 /PRNewswire via COMTEX/ --Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best Jun 24, 2020 · The contract from the U. , Jun 22, 2010 (BUSINESS WIRE) -Inovio Pharmaceuticals, Inc. S. Inovio's clinical studies of Jul 10, 2013 · Inovio's patented CELLECTRA electroporation delivery technology uses controlled, millisecond electrical pulses to create temporary pores in the cell membrane and allow significant cellular uptake Feb 16, 2023 · INOVIO plans to use the standard needle in the next trial involving INO-3107. Cardigant to Develop Electroporation-Based Intravascular Drug Delivery System Based on Inovio Patents and Technology Jun. , Oct. It consists of a pulse generator and a needle-electrode applicator. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. Nov 20, 2020 · Interim review in newly diagnosed glioblastoma patients provides OS18 data, demonstrates immunogenicity and tolerability in a majority of patients INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced today that data from the company's novel combination Oct 21, 2024 · INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP Dec 14, 2021 · INOVIO completes enrollment of REVEAL2 Long-term data favorable from REVEAL1 INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous Nov 9, 2021 · INO-4800, INOVIO's DNA vaccine candidate against SARS-CoV-2, is composed of a precisely designed DNA plasmid that is injected intradermally followed by electroporation using a proprietary smart The primary aim of this study was to assess protective capabilities of optimized DNA vaccines delivered using Inovio's proprietary electroporation system against simian immunodeficiency virus (SIV), which is closely related to human immunodeficiency virus (HIV). INOVIO plans to use the standard needle in the next trial involving INO-3107. gov ID NCT04398433 Sponsor Inovio Pharmaceuticals TITLE: INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) DATE: 22 August 2024 Inovio Biomedical & University of Southampton Collaborative Clinical Study Establishes Important Humoral Immune Response of Prostate Cancer DNA Vaccine Using Electroporation Aug. (NASDAQ:INO) announced today it has signed a definitive agreement to acquire all of Bioject Medical Technologies Inc. Sep 17, 2024 · INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP of Preclinical RD at INOVIO Abstract Title Dec 18, 2023 · The second is the presence of a number of manufacturers of electroporation devices, such as Inovio Pharmaceuticals, BTX, BEX CO, etc. (NYSE Amex: INO), a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent Dec 21, 2009 · SAN DIEGO, Dec 21, 2009 (BUSINESS WIRE) - Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that it has appointed Iacob Mathiesen, Ph. INO-3107 With Electroporation (EP) in Participants With HPV-6- and/ or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) ClinicalTrials. The studies were conducted by the HIV Vaccine Trials Network (HVTN). ’s assets, including pioneering needle-free jet injection technology, devices, and intellectual Mar 1, 2021 · INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18 Inovio has established that electroporation delivery of its SynCon (TM) DNA vaccines into skin tissue, an extension of its electroporation technology for delivering DNA vaccines into muscle, is able to facilitate potent neutralizing antibody responses that have protected ferrets in influenza challenge models and protected monkeys in a smallpox challenge model. (AMEX: INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today it has granted VGX Pharmaceuticals a worldwide non-exclusive license to its DNA delivery technology for intratumoral delivery of a proprietary gene to control the growth of melanoma and other cancers. Inovio will advance an integrated non-invasive delivery device combining Bioject’s jet injection technology with Inovio’s new needle-free, skin-surface electroporation (EP) technology. Most adverse events were mild and did not increase in frequency with age and subsequent dosing. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses SUBSCRIBE FOR UPDATES FROM INOVIO Register to receive email alerts for INOVIO press releases About Inovio DNA Medicines Technology DNA Medicines Pipeline Investors & Media For Patients Publications Careers Contact Us Safe Harbor Statement Expanded Sep 28, 2010 · Inovio Pharmaceuticals' HIV DNA Vaccine/Electroporation Delivery Technology Selected for NIH-Sponsored U. (NASDAQ:INO) announced today it has closed the transaction to acquire all of BioJect Medical Technologies Inc. 15, 2009- Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today it has granted an option to a commercial license to develop intravascular catheters using its proprietary electroporation technology to May 16, 2006 · Inovio Biomedical Corporation has announced that it has acquired, under a license with Sphergen SARL, rights to several patent families relating to the use of electroporation technology. Plumbline, based in South Korea, will fund all development and Oct 14, 2021 · INO-4800 is a SARS-CoV-2 Spike DNA-based vaccine that is delivered intradermally followed by electroporation (EP) using CELLECTRA ® 2000 and is currently undergoing clinical development. INOVIO uses proprietary delivery technology to help ensure our DNA medicines get where they need to be to make an impact – inside the cell, providing instructions to produce proteins to fight disease. Inovio's use of electroporation for gene therapy and DNA vaccines is a complement to Genetronics' existing electroporation therapy program. Jun 2, 2022 · Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. The company’s goal is to facilitate preventive immunization using its DNA vaccines against critical infectious diseases with unmet needs in large populations. In both cohorts, the proprietary CELLECTRA® electroporation device was used. Inovio’s HIV DNA vaccine Dec 12, 2023 · Intradermal delivery of DNA vaccines via electroporation (ID-EP) has shown clinical promise, but the use of needle electrodes is typically required to achieve consistent results. Joseph Kim, Ph. Mathiesen is an international expert in the field of electroporation delivery of biopharmaceuticals including DNA vaccines. Feb 1, 2010 · Inovio Biomedical (San Diego) is banking on this process, known as electroporation, to substantially change vaccine delivery. (INO:NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Inovio Pharmaceuticals, Inc. Here, delivery of a DNA vaccine targeting the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is achieved using noninvasive intradermal vacuum-EP (ID-VEP), which functions by pulling a small volume of skin Jun 22, 2010 · Enhanced Potency of SynCon (TM) DNA Vaccines Delivered Using Electroporation Highlighted in Molecular Therapy BLUE BELL, Pa. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total Aug 26, 2021 · Composed of a precisely designed DNA plasmid, INO-4800 is injected intradermally followed by electroporation using a proprietary smart device delivering the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response. 5 million in cash and stock. , July 10, 2013 / PRNewswire / -- Inovio Pharmaceuticals, Inc. New application of CELLECTRA® electroporation technology dramatically enhances ability of DNA therapy to stimulate blood vessel growth and recovery from debilitation caused by blocked arteries of the legs Results published in peer-reviewed Journal of Vascular Surgery BLUE BELL, Pa. Feb 9, 2011 · Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery Preclinical study demonstrating robust, sustained immune responses with non-invasive May 14, 2020 · Inovio Pharmaceuticals GeneOne Life Science, Inc. In both cohorts, the proprietary CELLECTRA ® electroporation device was used. Scientists Are Closer Than Ever To Reverse Aging. (NYSE MKT: INO) announced today that the use of its Skin electroporation devices have been assessed both in experimental animals and in the clinic. 22, 2012 / PRNewswire / - Inovio Pharmaceuticals, Inc. DNA vaccines are designed to offer broad cross-strain protection against viruses. INO-3107 is designed to elicit a targeted T cell response against HPV 6 and HPV 11, the HPV types responsible for causing RRP among other HPV-associated diseases. | Nasdaq Oct 10, 2023 · About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. How Does It Work? | Life Extended Nov 13, 2024 · The FDA previously granted INO-3107 Orphan Drug designation and Breakthrough Therapy designation and has advised INOVIO that it can submit a biologics license application under the FDA's accelerated approval program using data from INOVIO's already completed Phase 1/2 trial. Kate Broderick, Inovio's senior vice president of R&D, has been working on this technique for years, but The CELLECTRA ® electroporation device developed by Inovio Pharmaceuticals, Inc. , Jan 26, 2011 (BUSINESS WIRE) -Inovio Pharmaceuticals, Inc. Department of Defense will help Inovio scale up production of its coronavirus vaccine, which, unlike many rivals, relies on an electroporation device. The studies were conducted by the Featured Publications Leveraging a deep bench of expertise and foundational experience in DNA medicine development, we’re driving research that has the potential to transform treatment paradigms and improve patients’ lives. 23–25 The CELLECTRA-3P (Inovio Pharmaceuticals, Plymouth Meeting, PA) is a minimally invasive electroporation device that targets dermal and subcutaneous layers of the skin 26–28 with mild EP conditions and minimal tissue damage. The license also includes other patents involving the delivery of genes or drugs via ex vivo, intratumoral, and intramuscular electroporation. Pre-treatment gene expression signatures in MGMT-unmethylated pa-tients were statistically associated with OS18. Under the terms of the agreement, Inovio will Nov 7, 2023 · The U. Feb 7, 2011 · Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery Preclinical study demonstrating robust, sustained immune responses with non-invasive Feb 12, 2025 · INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) were published online in Nature Mar 14, 2016 · Non-invasive integrated injection and electroporation device to enhance mass immunization against flu, RSV, and pandemic/tropical infectious diseases using transformative immune-activating technology Inovio Pharmaceuticals, Inc. The team Feb 9, 2011 · Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery Preclinical study demonstrating robust, sustained immune responses with non-invasive Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses 1 day ago · INOVIO submitted the BLA under the FDA's Accelerated Approval program and has requested a priority review, which if granted, is expected to be completed within six months following the 60-day filing period. , to its Scientific Advisory Board. David Reardon, Principal Investigator, to present on June 6, 2022 at ASCO May 19, 2023 · INO-3107 was administered by intramuscular (IM) injection followed by electroporation (EP) on weeks 0, 3, 6, and 9. gov ID NCT04398433 Sponsor Inovio Pharmaceuticals Information provided by Inovio Pharmaceuticals (Responsible Party) Last Update Posted 2024-09-19 Download Expand all content Collapse all content Apr 24, 2024 · Inovio Pharmaceuticals has been granted a patent for an electroporation device with a needle array that includes an adjustable auto-lock assembly. J. The device allows for precise control over the movement of the needle array, enhancing the efficiency and effectiveness of electroporation procedures. Joseph Kim J. recently announced the peer-reviewed publication of results from two Phase I trials (HVTN 070 and HVTN 080) of its PENNVAX-B preventive HIV DNA vaccine delivered with a DNA adjuvant and with or without Inovio’s proprietary CELLECTRA electroporation delivery device. The license also includes other patents involving the delivery of genes or drugs via ex vivo, intratumoral, and intramuscular Nov 14, 2024 · INOVIO continued to advance plans for a Phase 3 trial of INO-3112 as a potential treatment for HPV-related oropharyngeal squamous cell carcinoma also known as throat cancer, through ongoing May 27, 2022 · Central Nervous System Tumors Session Abstract #2004: Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. Sep 3, 2025 · RKS worked with VGX on an NIH funded innovation program to develop a DNA Vaccine delivery device that leveraged electroporation technology to increase the uptake and effectiveness of the vaccine into the body’s cell structure. May 14, 2020 · Results Will Be Presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting INOVIO (NASDAQ: INO) today announced that 85 percent (44 out of 52) of patients newly diagnosed with the deadly brain cancer glioblastoma multiforme (GBM) who received the company's DNA medicine INO-5401, in combination with INO-9012 and PD-1 inhibitor Libtayo® (cemiplimab), were alive for at May 25, 2020 · INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. After injecting the DNA medicine into either skin or muscle tissue, CELLECTRA uses electroporation (brief May 26, 2021 · Inovio's device uses a technique called electroporation to sneak a DNA vaccine into cells. As an example of potential applications May 8, 2023 · In the first cohort, patients were dosed with a standard needle, while in the second, an exploratory side port needle was used to deliver INO-3107. Sep 13, 2010 · DNA Vaccine Delivered Using Electroporation Shows Potential to Treat Cervical Cancer and Precursor Dysplasias; Vaccine to Start Phase II in Early 2011 BLUE BELL, Pa. Inovio's CEO, Dr. Oct 13, 2022 · About INO-3107 INO-3107 is INOVIO's clinical-stage DNA medicine product candidate being developed as a potential treatment for RRP. Inovio's electroporation systems have been shown to increase cellular uptake of a DNA vaccine 1000 Feb 12, 2025 · In this phase 1/2 trial, the authors show that INO-3107, a DNA immunotherapy designed to elicit an immune response against HPV-6 and -11 recurrent respiratory papillomatosis, is well Mar 3, 2010 · Inovio’s proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Department of Defense (DoD) to support the large-scale manufacture of the company's proprietary CELLECTRA ® 3PSP smart device and the procurement of CELLECTRA ® 2000 devices, which are used to deliver INO-4800 directly into the skin. , Sep 13, 2010 (BUSINESS WIRE) - Inovio Pharmaceuticals, Inc. Joseph Kim, said, "This leukemia study expands Inovio's long-standing relationship with the University of Southampton into an important disease area and moves our first fully automated injection-electroporation delivery product into human studies. Jul 8, 2008 · SAN DIEGO & BLUE BELL, Pa. , Jul 07, 2008 (BUSINESS WIRE) -- Inovio Biomedical Corporation (AMEX:INO), a developer of electroporation-based DNA vaccine delivery technology, and VGX Pharmaceuticals 510 (k) Premarket NotificationFDA Home Medical Devices Databases Nov 13, 2024 · Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial Jul 5, 2006 · SAN DIEGO-- (BUSINESS WIRE)--July 5, 2006--Inovio Biomedical Corporation (AMEX:INO - News) announced today that it has exercised an existing option with RMR, LLC to license certain patented technology relating to the delivery of gene-based therapeutics into skin. Feb 22, 2012 · Electroporation delivery platform presents new avenue to enable development of targeted RNA-based therapies for untreatable diseases and conditions BLUE BELL, Pa. 5 months after the second dose. DNA is injected during insertion of the needles and, therefore, distributed along the entire path of the needle-electrode so that a larger portion of muscle cells are covered by both DNA and the electrical Mar 3, 2010 · New Hand-Held, Cordless Electroporation Device Designed to Facilitate Mass Vaccination SAN DIEGO, Mar 03, 2010 (BUSINESS WIRE) - Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA(R)-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA Jul 10, 2013 · BLUE BELL, Pa. Aug 9, 2021 · Composed of a precisely designed DNA plasmid, INO-4800 is injected intradermally followed by electroporation using a proprietary smart device delivering the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response. 5 months Dr. Mar 14, 2016 · Inovio will pay Bioject $5. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted Mar 14, 2016 · Inovio will integrate needle-free injection with needle-free electroporation delivery in next-generation device for large-population vaccine administration Inovio Pharmaceuticals, Inc. Dr. (NASDAQ:INO) announced today that it has received a new $5 million grant from the Bill & Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRA® 3PSP proprietary smart device for the intradermal delivery of INO-4800, a DNA vaccine for COVID-19. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INOVIO Pharmaceuticals for their experimental vaccine INO-3107 as a potential treatment for patients with recurrent respiratory papillomatosis based on data from Phase 1 and 2 of the clinical trial. Jun 23, 2020 · PLYMOUTH MEETING, Pa. May 15, 2019 · Inovio Pharmaceuticals Inc. Initial human data has shown this method can safely and significantly increase gene expression and immune responses. . The acquisition expands Genetronics' intellectual property in electroporation, expands the number of agreements with major pharmaceutical companies, and provides for the near-term initiation of a Phase I/II Inovio will advance an integrated non-invasive delivery device combining Bioject’s jet injection technology with Inovio’s new needle-free, skin-surface electroporation (EP) technology. Results: INO-4800 appeared well tolerated with no treatment-related serious adverse events. (NYSE MKT: INO) announced today the publication of positive immunological effects in preclinical animal models of optimized electroporation (EP) parameters for its minimally invasive skin (intradermal) EP delivery devices in the peer-reviewed journal Feb 13, 2009 · VGX Pharmaceuticals today announced the filing of a Device Master File (MAF) amendment with the U. , June 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has received $71 million funding from the U. If approved, INO-3107 would be INOVIO's first commercial product and the first DNA medicine available in the United States. Army Human Clinical Trial Phase I Study of PENNVAX (TM)-G /MVA-CMDR Will Assess Safety Inovio Pharmaceuticals, Inc. "The potential to have a meaningful new treatment for RRP brings Inovio to monetize electroporation technology for electrochemical and cytokine tumor therapies BLUE BELL, Pa. 4, 2012 / PRNewswire / - Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. Inovio's new minimally-invasive intradermal device is based on its electroporation delivery platform in which controlled, millisecond electrical pulses create permeability in cell membranes and enable dramatic uptake of biological material previously injected into targeted muscle or skin tissue. (OTC Bulletin Board Feb 7, 2011 · While current Inovio electroporation devices have been shown to be safe and well-tolerated in studies for delivering the company's DNA vaccines, Inovio has been trying to achieve the most optimal device characteristics to allow for mass vaccinations. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. Patients underwent surgical debulking within 14 days prior to first dose, with office laryngoscopy and staging at screening and weeks 6, 11, 26, and 52. , March 15, 2011 / PRNewswire / - Inovio Pharmaceuticals, Inc. Oct 11, 2021 · INO-4800, INOVIO's DNA vaccine candidate against SARS-CoV-2, is composed of a precisely designed DNA plasmid that is injected intradermally followed by electroporation using a proprietary smart device, which delivers the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response. Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses Inovio Pharmaceuticals, Inc. President, Chief Executive Officer, Director xxx Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation Feb 22, 2012 · Electroporation has a well-established track record of delivering useful drugs and biologics into cells to perform their useful function. , and accordingly the devices have some differences. Food and Drug Administration (FDA) for its patented CELLECTRA ® adaptive constant current electroporation device for use with intradermal electroporation (ID-EP). Inovio Inc cellectra 2000 adaptive constant current electroporation device Cellectra 2000 Adaptive Constant Current Electroporation Device, supplied by Inovio Inc, used in various techniques. , July 18, 2013 /PRNewswire/ - Inovio Pharmaceuticals, Inc. It has just unveiled a new clinical-grade, miniaturized device designed to deliver a variety of DNA vaccines, opening the door to push its healthy pipeline of new-style preventive and therapeutic vaccines into human trials. (NYSE MKT: INO) announced today the peer-reviewed publication of results from two phase I trials (HVTN 070 and HVTN 080) of its PENNVAX ® -B preventive HIV DNA vaccine delivered with a DNA adjuvant and with or without Inovio's proprietary CELLECTRA ® electroporation delivery device. Inovio Biomedical Corporation (AMEX:INO) announced today that it has exercised an existing option with RMR, LLC to license certain patented technology relating to the delivery of gene-based therapeutics into skin. ’s assets including pioneering needle-free jet Subscribe for updates from inovio Register to receive email alerts for INOVIO press releases Email Alerts Mailing Lists * ClinicalTrials. ; Defense Advanced Research Projects Agency Completed Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers Ebola Vaccine United States Inovio Pharmaceuticals Mar 12, 2020 · INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) and Plumbline Life Sciences (XKRX: 222670) today announced a collaboration to co-develop a novel animal health vaccine for African swine fever (ASF) virus. The drug is delivered intramuscularly and intradermally with five needles that are hidden by a shroud so that patients aren’t frightened by the experience. GlobalData’s report on Inovio Pharmaceuticals gives a 360-degree view of the company including A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle SUBSCRIBE FOR UPDATES FROM INOVIO Register to receive email alerts for INOVIO press releases May 22, 2006 · The Inovio electroporation device makes use of two standard disposable syringes with needles, which is used for both injection and application of electrical pulses (Fig 1, lower panel). Jan 26, 2011 · Potent Immune Responses Induced by DNA Vaccines Delivered by Intradermal Electroporation Pave Way for Prophylactic Vaccine Applications BLUE BELL, Pa. The rights Inovio has licensed include two patents with broad claims regarding electroporation of nucleic acids Nov 14, 2024 · INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases Jul 8, 2008 · Inovio has made tremendous strides in validating electroporation-based DNA vaccine delivery with human data in the last year, and we believe that Inovio’s patents and technology platform, partnerships, and clinical programs will provide synergy with VGX’s vaccine development focus and asset base. Nucleic acid-based medicines need a pathway into the cell to work effectively. 4 days ago · Inovio Pharmaceuticals, Inc. 5, 2009- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today new data representing what Inovio believes to be the first demonstration of a Nov 9, 2021 · About INO-4800 INO-4800, INOVIO's DNA vaccine candidate against SARS-CoV-2, is composed of a precisely designed DNA plasmid that is injected intradermally followed by electroporation using a proprietary smart device, which delivers the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response. The Company has been developing the CELLECTRA ® device as its lead clinical device for delivering DNA vaccine and therapy products Learn how Inovio's electroporation technology works. May 7, 2025 · An Open-label Multi-center Study of INO-3107 With Electroporation (EP) in Subjects With HPV-6- and/or HPV-11-associated Recurrent Respiratory Papillomatosis (RRP) CEO CORNER Dr. (NYSE Amex: INO) announced today that its next generation surface skin electroporation technology was successfully used to significantly enhance the delivery of small Sep 22, 2021 · About INO-4800 INOVIO's DNA vaccine candidate against SARS-CoV-2, INO-4800, is composed of a precisely designed DNA plasmid that is injected intradermally followed by electroporation using a proprietary smart device, which delivers the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response. The European Commission granted INO-3107 Orphan Drug designation. The Inovio Elgen 1000 Electroporation Applications System is a newer generation of electroporation systems by Inovio. The vaccine will be developed using Inovio's SynCon ® technology and delivered using CELLECTRA ® efficacy-enabling devices. Jan 28, 2010 · Inovio has established that electroporation delivery of its SynCon TM DNA vaccines into skin tissue, an extension of its electroporation technology for delivering DNA vaccines into muscle, is able Oct 23, 2025 · INOVIO is advancing novel immunotherapy technologies to reshape the future of treating and preventing infectious diseases and cancer. Animals receiving an NCI vaccine were challenged 14 weeks after a four-dose vaccination regime with a highly pathogenic strain of SIV New Preclinical Data Paves Way for Large Scale Vaccine Administration BLUE BELL, Pa. is currently being assessed in clinical studies for investigational purposes, for both prophylactic and therapeutic indications. About Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a Conclusions: INO-5401 + INO-9012 has an acceptable risk/benefit profile and elicits robust immune responses that correlate with enhanced survival when administered with cemiplimab and RT/TMZ to newly diagnosed GBM patients. iikr7 zj 1zz9oy uea hxiyojm wmtcu eylu9l senql qx8jf4 bmgpy